Perbandingan Tingkat Kepatuhan Minum Obat pada Penderita Skizofrenia dengan Indeks Massa Tubuh Normal dengan Indeks Massa Tubuh Tidak Normal di RSUD Dr. Pirngadi Medan Tahun 2026

Ritha Mariati Sembiring; Reinaldy Pangihutan Hutasoit; Yance Roberta Tobing; Karina Mutiarani Halawa; David Renaldy Tampubolon; Welni Ratna Sari Halawa

doi:10.47861/usd.v4i1.1774

Authors

Ritha Mariati Sembiring Universitas HKBP Nommensen Medan
Reinaldy Pangihutan Hutasoit Universitas HKBP Nommensen Medan
Yance Roberta Tobing Universitas HKBP Nommensen Medan
Karina Mutiarani Halawa Universitas HKBP Nommensen Medan
David Renaldy Tampubolon Universitas HKBP Nommensen Medan
Welni Ratna Sari Halawa Universitas HKBP Nommensen Medan

DOI:

https://doi.org/10.47861/usd.v4i1.1774

Keywords:

Schizophrenia, Medication Adherence, Body Mass Index, AntipsychoticsIndex

Abstract

Schizophrenia is a chronic mental disorder that requires long-term antipsychotic therapy. Medication adherence plays an important role in treatment success but is often affected by drug side effects such as weight gain, which impacts Body Mass Index (BMI). Changes in BMI may influence patient motivation and adherence to treatment. This quantitative study used a cross-sectional design conducted at Dr. Pirngadi General Hospital Medan from January to February 2026. A total of 106 schizophrenia patients were selected using quota sampling. Medication adherence was measured using the Morisky Medication Adherence Scale-8 (MMAS-8), and BMI was calculated based on weight and height measurements. Data were analyzed using the Chi-Square test with a 95% confidence level. Most respondents had abnormal BMI (72 patients; 67.9%), and high medication adherence was found in 74 patients (69.8%). In the normal BMI group, most patients had high adherence (30 patients; 88.2%), while in the abnormal BMI group, high adherence was found in 44 patients (61.1%). Chi-Square analysis showed a significant relationship between BMI and medication adherence in schizophrenia patients (p=0.017).

References

Agarwal, S. M., Stogios, N., Ahsan, Z. A., Lockwood, J. T., Duncan, M. J., Takeuchi, H., et al. (2022). Pharmacological interventions for prevention of weight gain in people with schizophrenia. Cochrane Database of Systematic Reviews, 10(2). https://pmc.ncbi.nlm.nih.gov/articles/PMC9528976/

Ali, T., Sisay, M., Tariku, M., Mekuria, A. N., & Desalew, A. (2021). Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies. PLOS ONE, 16(9). https://pubmed.ncbi.nlm.nih.gov/34506552/

Amir, N. (2017). Skizofrenia. Dalam Buku ajar psikiatri (edisi ke-3, hlm. 184–202). Jakarta: Fakultas Kedokteran Universitas Indonesia.

Cahaya, N., Kristina, S. A., Widayanti, A. W., & Green, J. (2022). Interventions to improve medication adherence in people with schizophrenia: A systematic review. Patient Preference and Adherence, 16(2). https://pmc.ncbi.nlm.nih.gov/articles/PMC9444034/

Dickerson, F., Khan, S., Origoni, A., Rowe, K., Katsafanas, E., Harvin, A., et al. (2024). Risk factors for natural cause mortality in schizophrenia. JAMA Network Open, 7(9). https://pmc.ncbi.nlm.nih.gov/articles/PMC11388031/

Figueira, J. A. V., Ochoa, A. D. S., Erazo, L. M. V., Dutazaka, G. M. G., & Bigman, G. P. (2025). Exploring the nutritional status in adults with chronic schizophrenia: A cross-sectional study in Ecuador. Frontiers in Nutrition, 12. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1658703/full

Fitrikasari, A., & Kartikasari, L. (2022). Buku ajar skizofrenia (hlm. 4–56). Semarang: UNDIP Press.

Guo, J., Lv, X., Liu, Y., Kong, L., Qu, H., & Yu, W. (2023). Influencing factors of medication adherence in schizophrenic patients: A meta-analysis. Schizophrenia, 9(1). https://pubmed.ncbi.nlm.nih.gov/37188714/

Hany, M., Rehman, B., Rizvi, A., & Chapman, J. (2024). Schizophrenia. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK539864/

Hany, M., & Rizvi, A. (2024). Schizophrenia. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK539864/

Ke, M., Zhou, T., Pu, C., Cheng, Z., Han, X., Yang, L., et al. (2024). Bidirectional relationship between weight gain and cognitive function in first-episode schizophrenia: A longitudinal study in China. Brain Sciences, 14(4). https://www.mdpi.com/2076-3425/14/4/310

Lestari, N. F., Sawitri, E., & Fitriany, E. (2022). Kepatuhan minum obat dan indeks massa tubuh (IMT) berhubungan dengan tekanan darah pasien hipertensi prolanis di Puskesmas Segiri Kota Samarinda. Jurnal Medika Karya Ilmiah Kesehatan, 7(1).

Lestari, R., Yusuf, A., Hargono, R., Setyawan, F. E. B., Hidayah, R., & Ahsan. (2020). Adapting to people with schizophrenia: A phenomenological study on a rural society in Indonesia. Indian Journal of Psychological Medicine, 43(1). https://pmc.ncbi.nlm.nih.gov/articles/PMC8295571/

Monteleone, P., Cascino, G., Monteleone, A. M., Rocca, P., Rossi, A., & Bertolino, A., et al. (2021). Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in real-life settings. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 109(2). https://www.sciencedirect.com/science/article/abs/pii/S0278584621000099

Putri, I. A., Amnan, & Maharani, B. F. (2022). Skizofrenia: Suatu studi literatur. Journal of Public Health and Medical Studies, 1(1), 1–11.

Rasyid, M. (2021). Pengaruh terhadap indeks massa tubuh (IMT). Jurnal Medika Utama, 7(1094).

Rohmi, F., & Pratiwi, R. P. (2022). Factors affecting medication adherence among patients with schizophrenia: A literature review.

Susanti, D., Paramita, P., & Antaria, A. (2022). Analisis faktor kepatuhan minum obat pasien skizofrenia di Poli Mentari Puskesmas Kecamatan Kalideres. Jurnal Kesehatan Masyarakat Indonesia, 1(2), 25–31. https://jurnal.unimus.ac.id/index.php/jkmi

World Health Organization. (2022). Schizophrenia. https://www.who.int/news-room/fact-sheets/detail/schizophrenia

World Health Organization. (2023). Adherence to long-term therapies: Evidence for action.

World Health Organization. (2023). Mental health gap action programme (mhGAP) guideline for mental, neurological and substance use disorders. https://www.who.int/publications/i/item/9789240084278

World Health Organization. (2025). Body mass index (BMI). https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/body-mass-index

World Health Organization. (2025). Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

Yong, N., Pan, J. Y., Li, X., Yu, L., & Hou, X. (2022). Factors influencing obesity in deficit schizophrenia patients in the community: A cross-sectional study. European Journal of Medical Research, 27(90). https://eurjmedres.biomedcentral.com/articles/10.1186/s40001-022-00706-y